VeriSIM Expects AI Use To Trim Margin For Failure In OTC Switches, Help Boost Revenue Margins

“It's a very expensive process for an OTC drug because you don't make significantly high margins compared to a blockbuster cancer drug. For pharma companies utilizing our platform, you can reduce that efficiency challenge and increase the probability of success,” says VeriSIM CEO Jo Varshney.